US Patent

US8859610 — Crystalline glycopyrrolate tosylate

Method of Use · Assigned to Dermira Inc · Expires 2033-02-28 · 7y remaining

Vulnerability score 45/100 Strong — defensible against typical IPR challenges

What this patent protects

This patent discloses methods of making glycopyrrolate salts and treating hyperhidrosis with those salts.

USPTO Abstract

Salts of glycopyrrolate, including solid forms thereof are herein disclosed. Methods of making glycopyrrolate salts and methods of treating hyperhidrosis with salts of glycopyrrolate are disclosed.

Drugs covered by this patent

glycopyrronium-tosylate (GLYCOPYRRONIUM TOSYLATE)

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-2398`	—	glycopyrronium-tosylate

Patent Metadata

Patent number: US8859610
Jurisdiction: US
Classification: Method of Use
Expires: 2033-02-28
Drug substance claim: No
Drug product claim: Yes
Assignee: Dermira Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.